等待開盤 02-06 09:30:00 美东时间
-1.525
-2.40%
今日重点评级关注:Canaccord Genuity:维持Wave Life Sciences Ltd."买入"评级,目标价从40美元升至43美元;花旗:维持Palantir Technologies"买入"评级,目标价从235美元升至260美元
02-04 12:15
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $84 to $92.
02-03 21:09
Cytokinetics EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Common Shares Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics Incorporated, has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: Thi
02-03 05:41
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. MYQORZO was recently approved by the U.S.
01-27 20:39
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从9美元升至50美元;韦德布什:维持Ardelyx, Inc."跑赢大市"评级,目标价从16美元升至19美元
01-22 15:09
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX Jan 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, KLA and WEX, on Wednesday. HIGHLIGHTS * IBM IBM.N : JP Morgan raises target price to $312 from $290 * KLA Corp KLAC.O : Deut
01-21 16:26
今日重点评级关注:HC Wainwright & Co.:维持Soleno Therapeutics"买入"评级,目标价从110美元升至120美元;富国银行:维持Soleno Therapeutics"超配"评级,目标价从106美元升至114美元
01-21 11:42
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $70 to $74.
01-20 22:49
Cytokinetics granted stock options and RSUs to 8 new employees on January 15, 2026, as inducements to employment. The RSUs vest over 3 years, while the stock options vest over 4 years with a 10-year term. The company focuses on developing cardiovascular therapies, with MYQORZO™ approved for obstructive HCM and under review in the EU. Additional pipeline candidates target heart failure.
01-20 21:00
Cytokinetics' CEO, Robert I. Blum, will present at the 44th J.P. Morgan Healthcare Conference on January 12, 2026. The event will be webcast live and archived for 90 days. Cytokinetics specializes in cardiovascular biopharmaceuticals, focusing on muscle biology to develop treatments for cardiac dysfunction. Its lead product, MYQORZO™ (aficamten), is approved for obstructive hypertrophic cardiomyopathy (HCM) and has received a positive opinion fro...
01-05 21:00